Anixa Biosciences, Inc. (ANIX)
$2.67-5.99%Close
BUYCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $91M
- Beta
- 0.60
- P/E (TTM)
- -8.75
- Short % float
- 4.19%
- Days to cover
- 3.7
- SI change
- +28.0%
- 1W
- -11.59%
- 1M
- -4.64%
- vs SPY 1W
- -11.45%
- vs SPY 1M
- -7.15%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 7
- GROWTH
- 47
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-42.3%
REV YoY-
ROE-70.4%
EPS YoY-
ROA-69.1%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-8.75
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B6.31
P/FCF-
EV/EBITDA-8.49
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.20
ALTMAN Z-
CURR RATIO8.54
ND/EBITDA-
BETA0.60
Company news
FAQ
- What is LOPJLB’s current signal on ANIX?
- LOPJLB’s latest quantitative signal on Anixa Biosciences, Inc. (ANIX) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is ANIX in?
- Anixa Biosciences, Inc. (ANIX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Anixa Biosciences, Inc. (ANIX) do?
- Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation…